The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...

Fourth-year biomedical engineering candidate Yining Zhu has been named a 2026 Siebel Scholar, an honor that recognizes students in bioengineering fields for exemplary achievement in academia, research ...

UNLV scientists successfully introduced nanoparticles with messenger RNA into the pancreas for the first time with 99% accuracy.

This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...

The U.S. IND CDMO market offers growth via extensive pipelines in oncology and rare diseases, driven by technological advancements, outsourcing trends, regulatory efficiencies, and modular GMP ...

The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to ...

CHICAGO--(BUSINESS WIRE)--#BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for ...

Biochemistry is considered a very challenging subject due to its complex, interdisciplinary subject matter that combines advanced biology and chemistry, a heavy workload, and rigorous lab components.

INOVIO (NASDAQ: INO) announced that results from its Phase 1 proof-of-concept trial evaluating DNA-encoded monoclonal antibodies (DMAbs) for COVID-19 have been published in Nature Medicine. The ...